Japanese Journal of Clinical Oncology Advance Access published online on November 8, 2008
Japanese Journal of Clinical Oncology, doi:10.1093/jjco/hyn119
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author (2008). Published by Oxford University Press. All rights reserved
Oral Fluoropyrimidines (Capecitabine or S-1) and Cisplatin as First Line Treatment in Elderly Patients with Advanced Gastric Cancer: A Retrospective Study
1 Division of Hematology-Oncology
2 Division of Gastroenterology, Department of Internal Medicine, College of Medicine, Pusan National University, Busan, Korea
For reprints and all correspondence: Joo Seop Chung, Hematology-oncology Division, Department of Internal Medicine, Pusan National University Hospital, 1-10 Ami-Dong, Seo-Gu, Busan 602-739, Korea. E-mail: hemon{at}pusan.ac.kr
Received August 10, 2008; accepted September 29, 2008
Background: This study aimed to evaluate the safety and efficacy of oral fluoropyrimidines and cisplatin therapy in elderly patients with untreated advanced gastric cancer (AGC) retrospectively. In addition, we evaluated the relative activity and toxicity of these agents in this patient population.
Methods: Clinical data from 72 patients with previously untreated AGC, who were treated with capecitabine/cisplatin and S-1/cisplatin, were reviewed. Oral fluoropyrimidines were administered orally twice a day on Days 1–14. The dose of capecitabine was 1250 mg/m2 and that of S-1 was 50 mg [body surface area (BSA) < 1.5 m3] or 60 mg (BSA > 1.5 m3) twice a day. Cisplatin was administered intravenously on Day 1 (before the first dose of capecitabine or S-1) at a dose of 70 mg/m2 over a 2 h period. The chemotherapy cycle was of 3 weeks (with oral capecitabine or S-1).
Results: Thirty-two and 40 patients received the S-1 and capecitabine regimens, respectively, and were included in the analysis. The S-1 protocol had a response rate of 40.6%, a median time-to-progression (TTP) of 5.4 months and a median survival of 9.6 months. The capecitabine had a response rate of 55%, a median TTP of 5.9 months and a median survival of 10.2 months. Each protocol had a similar incidence of Grade 3 or 4 adverse events. However, there was a higher rate of the hand–foot syndrome (6 versus 37%) and diarrhea (25 versus 32%) in the capecitabine group.
Conclusion: Oral fluoropyrimidines and cisplatin in elderly patients with untreated AGC showed encouraging results. The treatment was well tolerated with a manageable toxicity profile. The comparison of S-1 with capecitabine showed that capecitabine had a slightly higher response rate (statistically not significant) in addition to a higher rate of adverse events such as the hand–foot syndrome and diarrhea. These data should be warranted with further prospective studies.
Key Words: oral fluoropyrimidines • cisplatin • elderly • advanced gastric cancer